[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-366980-105":59,"doc-detail-366980-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","melanoma-associated-antigen-a4-a-cancertestis-antigen-as-a-target-for-adoptive-t-cell-receptor-t-cell-therapy","Melanoma-associated antigen A4 - A cancer/testis antigen as a target for adoptive T-cell receptor T-cell therapy","","T-cell receptor (TCR) T-cell therapies are adoptive cell therapies in which patient cells are engineered to express TCRs specific for cancer antigens and infused back into the patient. TCR recognition depends on antigen presentation by the human leukocyte antigen system, enabling responses to intracellular antigens. Cancer/testis antigens (CTAs) are expressed in cancer and immune-privileged germline sites. Melanoma-associated antigen A4 (MAGE-A4) is a prominent intracellular CTA found in healthy testis and placenta and across diverse tumor types, making it a key target for MAGE-A4 TCR T-cell therapy. The article reviews preclinical and clinical development, emphasizing characterization of off-target and on-target/off-tumor effects and reporting ten clinical trials with manageable safety and signals of efficacy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/melanoma-associated-antigen-a4-a-cancertestis-antigen-as-a-target-for-adoptive-t-cell-receptor-t-cell-therapy/366980/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/melanoma-associated-antigen-a4-a-cancertestis-antigen-as-a-target-for-adoptive-t-cell-receptor-t-cell-therapy/366980.png","ImageObject",300,407,{"name":92,"@type":93},"pixelkiddo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How do TCR T-cell therapies work in adoptive cell therapy?","Question",{"text":112,"@type":113},"Patient T cells are engineered to express TCRs that target specific cancer antigens, then infused back into the patient. Recognition relies on antigen presentation through the HLA system.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why is MAGE-A4 considered a prime target for TCR T-cell therapy?",{"text":117,"@type":113},"MAGE-A4 is an intracellular cancer/testis antigen expressed in healthy testis and placenta as well as many cancers. Its expression pattern, immunogenicity, and potential role in tumorigenesis support it as a target.",{"name":119,"@type":110,"acceptedAnswer":120},"What development and safety considerations does the article emphasize for TCR therapies?",{"text":121,"@type":113},"It highlights the need for extensive preclinical characterization of potential off-target effects and on-target but off-tumor effects, and reviews related strategies to improve efficacy and safety.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},366980,1790211854,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090883892,"https://ap-avatar.wpscdn.com/avatar/e00115db34f3e0f11b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1790152879550218658","Author Manuscript Author Manuscript Author Manuscript Author Manuscript  \n\n| | HHS Public Access\u003Cbr>Author manuscript\u003Cbr>Cancer Treat Rev. Author manuscript; available in PMC 2026 March 08. |\n| --- | --- |\n\nPublished in final edited form as:  \nCancer Treat Rev. 2025 March ; 134: 102891. doi:10.1016/j.ctrv.2025.102891 .  \nMelanoma-associated antigen A4: A cancer/testis antigen as a target for adoptive T-cell receptor T-cell therapy  \nGabrielle Knaflera,1 , Alan L. Hob, Kathleen N. Moorec, Seth M. Pollackd, Jean-Marc Navenote, Joseph P. Sandersonf,*  \na Envision Pharma Group Fairfield CT USA  \nb Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Medical College of Cornell University New York NY USA  \ncStephenson Cancer Center, University of Oklahoma Health Sciences Center Oklahoma City OK USA  \ndLurie Cancer Center, Department of Medicine, Northwestern University Feinberg School of  \nMedicine Chicago IL USA eAdaptimmune Philadelphia PA USAfAdaptimmune Abingdon UK  \nAbstract  \nT-cell receptor (TCR) T-cell therapies are adoptive cell therapies in which patient cells are engineered to express TCRs targeting specific cancer antigens and infused back into the patient.  \nSince TCR recognition depends on antigen presentation by the human leukocyte antigen system, TCRs can respond to intracellular antigens. Cancer/testis antigens (CTAs) are a large family of proteins, many of which are only expressed in cancerous tissue and immune-privileged germline sites. Melanoma-associated antigen A4 (MAGE-A4) is an intracellular CTA expressed in healthy testis and placenta, and in a range of cancers, including esophageal, head and neck, gastric, ovarian, colorectal, lung, endometrial, cervical, bladder, breast and prostate cancers;  \nsoft tissue sarcomas; urothelial and hepatocellular carcinomas; osteosarcoma; and melanoma.  \nThis expression pattern, along with the immunogenicity and potential role in tumorigenesis of MAGE-A4 make it a prime target for TCR T-cell therapy. We outline the preclinical and clinical development ofTCR T-cell therapies targeting CTAs for treatment of solid tumors, highlighting the need for extensive preclinical characterization of putative off-target, and potential on-target but off-tumor, effects. We identified ten clinical trials assessing TCR T-cell therapies targeting MAGE-A4 . Overall, manageable safety profiles and signals of efficacy have been observed,  \nThis is an open access article under the CC BY license ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)).  \nCoAtrrestheptonimig authorf writing. .[Joseph.Sanderson@adaptimmune.com](Joseph.Sanderson@adaptimmune.com) (J.P. Sanderson).  \nAuthor contributions  \nGK wrote the first draft; all authors critically reviewed the manuscript and approved the final version for submission. Declaration of competing interest  \nThe authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.  \nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript  \nKnafler et al. Page 2  \nespecially in patients with advanced synovial sarcoma, myxoid/round cell liposarcoma, ovarian, head and neck, and urothelial cancers, with one TCR T-cell therapy approved by the US Food and Drug Administration in August 2024. We also review the limitations, and strategies to enhance efficacy and improve safety, of these therapies, and summarize related immunotherapies targeting MAGE-A4 .  \nKeywords  \nT-cell therapy; Melanoma-associated antigen; Cancer/testis antigen; Adoptive cell therapy; T-cell receptor therapy  \nIntroduction  \nImmunotherapy has improved treatment options and outcomes for many people with cancer; however, responses are often limited in non-hematologic advanced solid tumors.  \nChimeric antigen receptor (CAR) T-cell therapies approved by the US Food and Drug Administration (FDA) for various hematologic malign","cbCainE4xfhiD4DI","https://ap.wps.com/l/cbCainE4xfhiD4DI","pdf",1308350,25,"English","# Abstract\n# Introduction\n## Tumor antigen categories and specificity\n## Rationale for TCR-based adoptive cell therapy","[{\"question\":\"How do TCR T-cell therapies work in adoptive cell therapy?\",\"answer\":\"Patient T cells are engineered to express TCRs that target specific cancer antigens, then infused back into the patient. Recognition relies on antigen presentation through the HLA system.\"},{\"question\":\"Why is MAGE-A4 considered a prime target for TCR T-cell therapy?\",\"answer\":\"MAGE-A4 is an intracellular cancer/testis antigen expressed in healthy testis and placenta as well as many cancers. Its expression pattern, immunogenicity, and potential role in tumorigenesis support it as a target.\"},{\"question\":\"What development and safety considerations does the article emphasize for TCR therapies?\",\"answer\":\"It highlights the need for extensive preclinical characterization of potential off-target effects and on-target but off-tumor effects, and reviews related strategies to improve efficacy and safety.\"}]","Melanoma-associated antigen A4 - A cancer/testis antigen as a target for adoptive T-cell receptor T-cell therapy | PDF",1790168541,63,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b58c3cfd5d5fc5177aa11be851e6238a.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a76ad52ec1927023e455e5a8398e1f14.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0688ce7cee7efe82e4eb9b3e165ebf77.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fcfc2e6f2da2951aab9999f9a29f36d4.webp",980,1268]